The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzumab plus trastuzumab and docetaxel vs. placebo that was seen in the overall population. Therefore, COMACHI was conducted to confirm the efficacy and safety of this treatment regimen in this patient subgroup.
Methods
This was a phase IV study of pertuzumab plus trastuzumab and docetaxel in Japanese patients with histologically/cytologically confirmed inoperable or recurrent HER2-positive breast cancer. All patients received pertuzumab, trastuzumab, and docetaxel intravenously every 3 weeks until disease progression/unacceptable toxicity. The primary endpoint was investigator-assessed PFS. Secondary endpoints were overall survival (OS), investigator-assessed objective response rate, and duration of response (DoR). Safety was also assessed.
Results
At final analysis, median investigator-assessed PFS was 22.8 months (95% CI 16.9–37.5). From first dose, OS rate at 1 year was 97.7%; and at 2 and 3 years were 88.5% and 79.1%, respectively. Of the 118 patients with measurable disease at baseline, response rate was 83.9% (95% CI 77.3–90.5) and median investigator-assessed DoR was 26.3 months (95% CI 17.1–not evaluable). Treatment was well tolerated, with no new safety signals detected.
Conclusions
Our results suggest similar efficacy and safety for pertuzumab plus trastuzumab and docetaxel in Japanese patients compared with the overall population of CLEOPATRA, providing further support for this combination therapy as standard of care for Japanese patients with inoperable or recurrent HER2-positive breast cancer.
Key data from COMACHI were previously presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2019 (27 Sep–01 Oct 2019).
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Breast cancer is the second most common type of cancer and was the third most common cause of cancer-related mortality in 2018, accounting for 2,088,849 (11.6%) of new cancer diagnoses and 626,679 (6.6%) cancer-related deaths worldwide [1]. In Japan, there were 87,050 new cases of breast cancer reported in 2015 and 14,285 related deaths in 2017 [2, 3]. Overexpression or amplification of human epidermal growth factor receptor 2 (HER2) occurs in approximately one-fifth of all breast cancers and has been associated with a poor prognosis historically [4, 5]. Introduction of anti-HER2 agents for the treatment of patients with HER2-positive metastatic breast cancer has improved outcomes (median overall survival [OS] and 5-year survival rates) in these patients [6].
Pertuzumab plus trastuzumab and a taxane is now the recommended standard of care for the first-line treatment of patients with HER2-positive recurrent or metastatic breast cancer in both the National Comprehensive Cancer Network and the Japanese Breast Cancer Society Clinical Practice Guidelines [7, 8]. Dual HER2 blockade with pertuzumab plus trastuzumab and docetaxel as a first-line treatment for HER2-positive recurrent or metastatic breast cancer demonstrated superiority in progression-free survival (PFS), as assessed by an independent review committee (IRC), and in OS in the global phase III, randomized, placebo-controlled Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study (ClinicalTrials.gov number, NCT00567190) [9, 10]. Median IRC-assessed PFS (the primary endpoint) in the intention-to-treat population was improved by 6.1 months in the pertuzumab arm compared with the placebo arm (18.5 months vs. 12.4 months; stratified hazard ratio (HR) 0.62; 95% confidence interval (CI) 0.51–0.75; stratified log-rank P < 0.001) [9]. At the time of the PFS primary analysis, OS did not meet the stopping criteria for significance [9]. However, after an additional year of follow-up, superiority in OS was demonstrated [10]; median OS was not reached in the pertuzumab arm but was 37.6 months in the placebo arm (HR 0.66; 95% CI 0.52–0.84; P < 0.001) [10]. In the final analyses at a median follow-up of 99 months, median PFS and median OS in the pertuzumab arm were improved by 6.3 months (HR 0.69; 95% CI 0.59–0.81) and 16.3 months (HR 0.69; 95% CI 0.58–0.82), respectively [11].
Anzeige
However, in the primary analysis of PFS in CLEOPATRA, consistency of efficacy was not confirmed in Japanese patients [12]. Of the 26 patients included in the pertuzumab arm and the 27 patients included in the placebo arm, 14 (53.8%) and 11 (40.7%) patients experienced a PFS event, respectively, and median PFS was 12.5 months in the pertuzumab arm vs. 18.7 months in the placebo arm (stratified HR 1.63; 95% CI 0.70–3.78) [12]. In light of this, Japan’s Pharmaceuticals and Medical Devices Agency has since recommended confirmation of the efficacy of pertuzumab in Japanese patients [12]. Therefore, the COMACHI study (clinicaltrials.jp identifier, JapicCTI-132321) was conducted to confirm the efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy for Japanese patients with inoperable or recurrent HER2-positive breast cancer.
Methods
Study design
This was a phase IV, multicenter, single-arm study of pertuzumab plus trastuzumab and docetaxel in Japanese patients. Although the study was not a randomized, comparative study, key design components such as eligibility criteria and definition of endpoints were similar to those seen in the pertuzumab arm in the CLEOPATRA study [9].
Eligible patients were females aged ≥ 20 years who had histologically or cytologically confirmed inoperable or recurrent HER2-positive breast cancer (immunohistochemistry 3 + or in situ hybridization HER2: chromosome enumeration probe 17 ratio ≥ 2.0) and were candidates for chemotherapy, or had unresectable locally recurrent or new stage IV HER2-positive breast cancer. Additional inclusion criteria were the presence of measurable or unmeasurable lesions per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, a baseline left ventricular ejection fraction (LVEF) of ≥ 50%, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the use of appropriate contraception during and for ≥ 7 months after the last dose of study treatment. Key exclusion criteria were the identification of metastases to the central nervous system, a history of LVEF decline to < 50% during or after neoadjuvant/adjuvant trastuzumab therapy, a history of anticancer treatment for inoperable or recurrent breast cancer (epidermal growth factor receptor/anti-HER2 drug/vaccine, chemotherapy, two or more prior hormonal regimens), treatment history of approved or investigational tyrosine kinase/HER family inhibitors for breast cancer at any time (except for trastuzumab as neoadjuvant/adjuvant therapy), having prior systemic therapy for breast cancer as neoadjuvant/adjuvant therapy and a disease-free interval of < 12 months from the date of last taxane administration in neoadjuvant/adjuvant therapy until diagnosis of recurrence, and prior exposure to a cumulative dose of doxorubicin or liposomal doxorubicin that exceeded 360 mg per square meter of body-surface area or its equivalent.
All patients included in the study received a loading dose of pertuzumab (840 mg) and trastuzumab (8 mg/kg), followed by a maintenance dose (420 mg and 6 mg/kg, respectively) intravenously every 3 weeks until disease progression or unacceptable toxicity. Docetaxel (75 mg/m2) was also administered to all patients intravenously every 3 weeks. The recommended number of cycles for docetaxel was at least six; until Cycle 6, docetaxel was discontinued only if disease progression or uncontrollable adverse events occurred, and continuation of docetaxel beyond Cycle 6 was at the discretion of the investigator.
Anzeige
The study was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonisation E6 Good Clinical Practice (ICH-GCP-E6) guidelines, and local laws and regulations. Approval for the study protocol, any protocol amendments, and all material provided to the patients were obtained from the relevant institutional review board or ethics committee at each site. All patients provided written informed consent.
Endpoints
The primary endpoint was investigator-assessed PFS. Secondary endpoints were OS, investigator-assessed objective response rate (ORR), and duration of response (DoR). Safety and tolerability were also assessed. Disease control rate (the percentage of patients who achieved complete response [CR], partial response [PR], or stable disease) and investigator-assessed time to response were exploratory endpoints.
Investigator-assessed PFS was defined as the time from first dose to the first documented radiographic evidence of progressive disease according to RECIST v1.1, or death from any cause within 18 weeks after the last independent assessment of tumors. OS was defined as the time from first dose to death from any cause, and investigator-assessed ORR as the rate of PR or CR occurring after first dose and confirmed ≥ 28 days later per RECIST v1.1.
Assessments
Tumor assessments were performed every 9 weeks for the first 2 years, and then every 18 weeks thereafter, in accordance with RECIST v1.1, until the time of disease progression or death. Treatment decisions were made by the investigator on the basis of their assessment of disease progression.
LVEF assessments were performed at baseline, every 9 weeks during the treatment period, at the time of treatment discontinuation, and then every 18 weeks or less thereafter. Final LVEF assessments were performed 28–42 days after final administration.
Adverse events were monitored continuously throughout the study and were graded per the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.03. Patients with adverse events leading to treatment discontinuation were followed for as long as possible, until resolution of the event or stabilization of the patient’s condition.
Statistical methods
The target sample size for the study was 130 patients to ensure 80% statistical power at a two-sided significance level of 0.05 to reject the null hypothesis that the median PFS in the COMACHI study was less than 12.4 months, which was the observed median IRC-assessed PFS in the placebo arm of the primary analysis in the CLEOPATRA study [9]. Efficacy analyses were planned for patients in the intention-to-treat population, which included all patients who were enrolled in the study, and safety analyses for all patients who received ≥ 1 dose of a study drug. We also conducted an exploratory analysis of median PFS and 95% CI by demographic subgroups, and an exploratory, post hoc analysis of the efficacy of pertuzumab plus trastuzumab as a maintenance therapy in patients who intentionally discontinued docetaxel beyond Cycle 6.
All patients received treatment and were analyzed for both efficacy and safety. The Kaplan–Meier method was used to estimate the medians and the distribution of PFS, OS, and DoR. CI for medians was calculated using the Brookmeyer–Crowley method of log–log transformation. CIs for response rates were calculated using the Clopper–Pearson method. Safety analyses were descriptive.
Anzeige
Results
Patients
A total of 132 patients were enrolled in the study across 29 sites in Japan between November 2013 and September 2015. Primary analysis was performed to satisfy the protocol-defined trigger for primary analysis; the date of clinical cutoff for the primary analysis was June 7, 2018, with a median follow-up of 24.9 months. Final analysis was performed because it was concluded that there would not be a significant gain of information with a further follow-up, and the sponsor consequently closed the study. The clinical cutoff date for the final analysis was April 25, 2019, with a median follow-up of 46.9 months.
Patient demographics and baseline characteristics are shown in Table 1. The median age of patients was 56.5 years (range 34–81 years). The majority of patients had an ECOG performance status of 0 and a HER2 status of immunohistochemistry 3 + . Seventy (53.0%) patients were estrogen receptor-positive; 71 patients (53.8%) had stage IV disease and 81 patients (61.4%) had visceral metastasis at baseline. Approximately one-fifth of patients had received treatment with trastuzumab prior to study enrollment.
Table 1
Patient demographics and baseline characteristics in the intention-to-treat population
Characteristic
Patients (N = 132)
Female, n (%)
132 (100)
Median age, years (range)
56.5 (34–81)
ECOG performance status, n (%)
0
115 (87.1)
1
17 (12.9)
Stage of disease at initial diagnosis, n (%)
Stage I
8 (6.1)
Stage II
31 (23.5)
Stage IIIA
7 (5.3)
Stage IIIB
7 (5.3)
Stage IIIC
8 (6.1)
Stage IV
71 (53.8)
Site of disease, n (%)
Non-visceral
51 (38.6)
Visceral
81 (61.4)
Hormone-receptor status, n (%)
ER- and/or PgR-positive
72 (54.5)
ER- and PgR-negative
60 (45.5)
HER2 status by IHC/ISH, n (%)
IHC 2 + and ISH-positive
17 (12.9)
IHC 3 + and ISH-positive
IHC 3 + and ISH unknown
4 (3.0)
107 (81.1)
IHC unknown and ISH-positive
4 (3.0)
Recurrence
De novo metastatic disease
83 (62.9)
Recurrent metastatic diseasea
49 (37.1)
Disease-free interval (month)b,c
n
49
Mean (SD)
55.7 (41.7)
Median
44.3
Min–max
0.6–179.4
Prior therapies, n (%)
No
94 (71.2)
Yes
38 (28.8)
Anthracycline
25 (18.9)
Taxanes
22 (16.7)
Trastuzumab
30 (22.7)
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization, PgR progesterone receptor
aPatients with non-recurrence were classified as having "de novo metastatic disease”
bDisease-free interval is the time from completion of systemic treatment (chemotherapy) and/or surgery to the diagnosis of metastatic/recurrence disease
cPatients with a disease-free interval of < 1 month were not assumed to have “de novo metastatic disease”
Progression-free survival (primary endpoint)
At the primary and the final analyses, median investigator-assessed PFS was 22.8 months (primary analysis: 95% CI 16.9–34.8; final analysis: 95% CI 16.9–37.5) (Fig. 1). The lower limit of the 95% CI for median investigator-assessed PFS was above the preset threshold of 12.4 months; therefore, a median PFS of at least 12.4 months was demonstrated. From first dose of the study drug, PFS rates at 1 year and 2 years were 73.7% and 47.9%, respectively (Fig. 1b).
Fig. 1
Investigator-assessed PFS at the a primary analysis at the clinical cutoff date of June 7, 2018 and b final analysis at the clinical cutoff date of April 25, 2019
×
Key secondary endpoints
Median OS was not reached at the final analysis (Fig. 2) due to the small number of events (n = 42 patients [31.8%]). From first dose, OS rate at 1 year was 97.7% and at 2 and 3 years was 88.5% and 79.1%, respectively (Fig. 2).
Fig. 2
OS at the final analysis (clinical cutoff date: April 25, 2019)
×
Anzeige
Of the 118 patients with measurable disease at baseline, investigator-assessed response rate was 83.9% (95% CI 77.3–90.5), with a best overall response of CR in 11 patients (9.3%) and PR in 88 patients (74.6%) (Table 2). Median investigator-assessed time to response was 2.1 months (95% CI 2.0–2.1) and median investigator-assessed DoR was 26.3 months (95% CI 17.1–not evaluable [NE]). A further 16 patients (13.6%) had stable disease, giving a disease control rate of 97.5% (95% CI 94.6–100.0); three patients (2.5%) had progressive disease.
Table 2
Best overall response in patients with measurable disease at baseline (n = 118)
Best overall response
Patients, n (% [95% CI]) (n = 118)
Objective response
99 (83.9 [77.3–90.5)
Complete response
11 (9.3 [4.08–14.6])
Partial response
88 (74.6 [66.7–82.4])
Stable disease
16 (13.6 [7.38–19.74])
Progressive disease
3 (2.5 [0.00–5.38])
CI confidence interval
Exploratory analysis of efficacy
At the final analysis, estimated median PFS in each of the demographic subgroups was similar to that of the overall Japanese population (Table 3), with the exception of hormone-receptor status (positive and negative hormone-receptor status: median PFS = 18.9 months [n = 41; 95% CI 14.7–33.1] vs. 33.7 months [n = 29; 95% CI 20.6–NE]; Online Resource 1) and site of disease (non-visceral and visceral: median PFS = 37.5 months [n = 19; 95% CI 20.7– NE] vs. 18.4 months [n = 51; 95% CI 13.8–33.7]; Online Resource 2). Kaplan–Meier plots of median PFS for other demographic subgroups are shown in the supplementary materials (Online Resource 3–7). Compared with patients who continued docetaxel treatment beyond Cycle 6, discontinuation of docetaxel at Cycle 6 did not impact PFS irrespective of whether discontinuation was due to adverse event/lack of efficacy or not (Online Resource 8 and 9).
Table 3
Subgroup analyses of progression-free survival
n
Number of events, n (%)
Median PFS, months (95% CI)
HR (95% CI)
Overall population
132
70 (53.0)
22.8 (16.9–37.5)
–
Prior (neo)adjuvant therapya
Yes
38
18 (47.4)
27.7 (12.4–NE)
0.91 (0.53–1.56)
No
94
52 (55.3)
20.8 (16.9–38.8)
–
Age
< 65
96
53 (55.2)
22.8 (16.5–37.5)
1.29 (0.75–2.23)
≥ 65
36
17 (47.2)
33.1 (18.7–NE)
–
Site of disease
Non-visceral
51
19 (37.3)
37.5 (20.7–NE)
0.62 (0.37–1.06)
Visceral
81
51 (63.0)
18.4 (13.8–33.7)
–
HER2 status IHC/ISH
IHC ≤ 2 + and ISH-positive
21
13 (61.9)
16.5 (10.4–34.8)
–
IHC 3 +
111
57 (51.4)
22.9 (18.4–49.5)
0.66 (0.36–1.21)
HR status
ER- and/or PgR-positive
72
41 (56.9)
18.9 (14.7–33.1)
–
ER- and PgR-negative
60
29 (48.3)
33.7 (20.6–NE)
0.79 (0.49–1.27)
Menopausal status
Premenopausal
46
27 (58.7)
22.8 (16.6–49.5)
–
Postmenopausal
86
43 (50.0)
22.8 (14.6–NE)
1.05 (0.65–1.70)
Recurrence
De novo metastatic disease
83
48 (57.8)
20.7 (16.6–37.5)
–
Recurrent metastatic diseaseb
49
22 (44.9)
28.1 (16.7–NE)
0.77 (0.47–1.28)
CI confidence interval, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, IHC immunohistochemistry, ISH in situ hybridization, PFS progression-free survival, PgR progesterone receptor
aIncludes prior trastuzumab and/or chemotherapy (patients receiving hormonal therapy alone are included in the ‘No’ population)
bPatients with non-recurrence were classified as having "de novo metastatic disease”
Treatment exposure
Median duration of study treatment was 17.1 months (range 1.3–60.9) at final analysis. A total of 104 patients (78.8%) completed six cycles of docetaxel treatment; 48 patients (46.2%) discontinued docetaxel at Cycle 6 and 56 patients (53.8%) continued docetaxel beyond Cycle 6. Reasons for permanent discontinuation of docetaxel are presented in Online Resource 10.
By final analysis, 75 patients (56.8%) had withdrawn from study treatment due to lack of efficacy. Other reasons for withdrawal included withdrawal by patient (n = 12 [9.1%]), adverse events (n = 9 [6.8%]), and other reasons (patients who discontinued due to reasons unrelated to investigational medicinal product efficacy or safety; n = 36 [27.3%]).
Safety
Adverse events of any grade occurred in all patients, with a total of 3789 events reported. The most common any-grade adverse events occurring in ≥ 30% of patients were alopecia (n = 122 [92.4%]), diarrhea (n = 104 [78.8%]), and decreased neutrophil count (n = 83 [62.9%]) (Table 4). Grade ≥ 3 adverse events occurred in 127 patients (96.2%). The most common grade ≥ 3 adverse events occurring in ≥ 5% of patients were decreased neutrophil count (n = 82 [62.1%]), decreased white blood cell count (n = 67 [50.8%]), and febrile neutropenia (n = 42 [31.8%]) (Table 4). Any-grade and grade ≥ 3 peripheral neuropathy occurred in 50 patients (37.9%) and 1 patient (0.8%), respectively. Serious adverse events occurred in 33 patients (25.0%), with febrile neutropenia (n = 8; 6.1%) as the only serious adverse event that occurred in ≥ 5% of patients. Treatment-related adverse events occurred in 132 patients (100%). Adverse events leading to the discontinuation of the study drug were reported in 62 patients (47.0%) and adverse events leading to dose modification or interruption in 98 patients (74.2%). With regard to cardiac safety, only seven patients (5.3%) experienced a significant decline in LVEF (LVEF decrease ≥ 10% from baseline to < 50%) (Fig. 3). There were no adverse event-related deaths.
Table 4
Summary of adverse events, including all where any grade occurred in ≥ 30% or grade ≥ 3 occurred in ≥ 5%
Adverse event
Patients, n (%) (N = 132)
Any grade
Grade ≥ 3
Alopecia
122 (92.4)
0
Diarrhea
104 (78.8)
6 (4.5)
Neutrophil count decreased
83 (62.9)
82 (62.1)
Stomatitis
81 (61.4)
4 (3.0)
Taste abnormality
75 (56.8)
0
White blood cell count decreased
70 (53.0)
67 (50.8)
Loss of appetite
70 (53.0)
7 (5.3)
Nasopharyngitis
69 (52.3)
0
Malaise
65 (49.2)
0
Rash
63 (47.7)
1 (0.8)
Nausea
60 (45.5)
1 (0.8)
Peripheral edema
57 (43.2)
1 (0.8)
Injection-site reaction
53 (40.2)
0
Peripheral neuropathy
50 (37.9)
1 (0.8)
Muscle pain
50 (37.9)
1 (0.8)
Fever
45 (34.1)
1 (0.8)
Vomiting
42 (31.8)
1 (0.8)
Febrile neutropenia
42 (31.8)
42 (31.8)
Neutropenia
32 (24.2)
32 (24.2)
Anemia
22 (16.7)
9 (6.8)
Leukopenia
14 (10.6)
14 (10.6)
Fig. 3
Time-dependent change in LVEF
×
Anzeige
Discussion
In this phase IV, multicenter, single-arm study of pertuzumab plus trastuzumab and docetaxel, the investigator-assessed PFS, OS, and investigator-assessed ORR and disease control rate results suggest that the treatment combination is effective in Japanese patients, similar to the overall population assigned to the pertuzumab-treated arm in the pivotal CLEOPATRA study [9, 11].
Investigator-assessed PFS in the Japanese patients included in our study was numerically longer than the IRC-assessed PFS results observed in the overall population in the CLEOPATRA study (median PFS: 22.8 months vs. 18.5 months) [9, 11]. The slightly longer PFS observed in COMACHI compared with CLEOPATRA may be due to differences in patient characteristics between the two studies [9]. For example, COMACHI included a higher proportion of patients with non-visceral disease (although studies have reported comparable response rates for patients with or without visceral disease when treated with various chemotherapeutic agents) [13], a lower proportion of patients who received prior treatment with anthracyclines, and a lower proportion of patients with an ECOG performance status of 1. Similar to PFS, the results for time to response and DoR in our study also suggest that pertuzumab plus trastuzumab and docetaxel is effective in Japanese patients; the median DoR observed here was greater than that observed in the overall population of the CLEOPATRA 3-year follow-up study (26.3 months [95% CI 17.1–NE] vs. 20.2 months [95% CI 16.0–24.0]) [14].
As expected, subgroup analysis demonstrated a lower median PFS in patients with visceral metastasis, compared to those with non-visceral disease. Interestingly, the analysis also found a lower median PFS in patients with a positive hormone-receptor status, compared to those with a negative status. Overall, this suggests that it may be meaningful to consider adding hormone therapy to patients of this subgroup. In support of this, the recent PERTAIN study examining the efficacy of pertuzumab plus trastuzumab and an aromatase inhibitor (anastrozole or letrozole) in patients with HER2-positive and hormone-receptor-positive, metastatic/locally advanced breast cancer met its primary PFS endpoint (median PFS: 18.9 months vs. 15.8 months for trastuzumab alone; stratified HR 0.65; 95% CI 0.48–0.89; P < 0.01) [15]. Improved therapeutic outcomes of combined hormonal and trastuzumab therapy in this patient population have also been demonstrated in randomized phase III clinical trials, for example, the TAnDEM and eLEcTRA trials [16, 17]. Interestingly, discontinuation of docetaxel at Cycle 6 in our study did not reduce PFS in patients compared to those who continued beyond Cycle 6, suggesting that withdrawing docetaxel at Cycle 6 may reduce toxicity in patients without worsening prognosis. However, these analyses should be interpreted with caution because of their exploratory nature and non-randomized comparison with potential selection bias. Moreover, in contrast to our study, a systematic review of randomized controlled trials of first-line chemotherapy in patients with metastatic breast cancer found longer chemotherapy durations (≥ 6 cycles) to result in clinically meaningful improvements in PFS [18]. This discussion is particularly relevant given that there are currently no specific recommendations in the literature regarding how long chemotherapy should be continued after treatment response and while toxicity is manageable.
Study treatment exposure was similar between COMACHI and CLEOPATRA, with median durations of study treatment of 17.1 months and 18.1 months, respectively [9]. Treatment with pertuzumab plus trastuzumab and docetaxel was generally well tolerated in this study, with no new safety signals detected. There were also no clinically problematic changes in laboratory parameters, cardiac function, or vital signs in our study. Of note, incidence of febrile neutropenia and diarrhea occurred more frequently in COMACHI than in the pertuzumab arm of the primary CLEOPATRA study (31.8% vs. 13.8% and 78.8% vs. 66.8%, respectively) [9]. However, febrile neutropenia resulted in discontinuation of the study and concomitant medication in only one patient in COMACHI. Furthermore, the prophylactic use of granulocyte-colony stimulating factor in Japanese patients was approved in 2014; therefore, the higher incidence of febrile neutropenia in this study is not thought to be a significant concern in practice. In support of this, in the phase III randomized PEONY trial of Asian patients with early/locally advanced HER2 breast cancer treated with pertuzumab plus trastuzumab and docetaxel, concomitant use of prophylactic granulocyte-colony stimulating factor was permitted, with only four patients (1.8%) reported to develop febrile neutropenia [19]. Similar to the results observed in our study, a subgroup analysis of Asian patients in CLEOPATRA demonstrated a higher incidence of febrile neutropenia in Asian patients than in patients from other regions [20]. In contrast, Chinese patients with locally recurrent or metastatic HER2-positive breast cancer in the PUFFIN study appeared to have a lower incidence of febrile neutropenia than reported here and in the Asian and overall population in the CLEOPATRA study [21].
As this was a single-arm study, no comparator arm is available to allow for direct comparison of pertuzumab plus trastuzumab and docetaxel with placebo plus trastuzumab and docetaxel. Furthermore, although the similarities in study design and enrolled patient populations between COMACHI and CLEOPATRA have allowed some comparisons to be made, these should be interpreted with caution in light of their retrospective nature. Moreover, the present study did not include assessments of health-related quality of life, which has been shown to be crucial to overall patient outcomes. For example, a study of female survivors of breast cancer found that women with the highest social well-being quality-of-life score had a significantly reduced risk of mortality (95% CI 0.46–0.85; P = 0.002) and disease recurrence (95% CI 0.38–0.71; P < 0.001) [22]. However, in light of the efficacy and safety profile observed in COMACHI, it is reasonable to expect positive quality-of-life scores in Japanese patients receiving pertuzumab plus trastuzumab and docetaxel, as reported in the overall population in CLEOPATRA [23]. Finally, all patients in COMACHI received pertuzumab plus trastuzumab and docetaxel regardless of treatment-free intervals; patients with a short treatment-free interval whose disease has progressed on trastuzumab may be given alternative therapy options such as ado-trastuzumab emtansine [24]. However, it should be noted that ado-trastuzumab emtansine had not yet been approved in Japan upon initiation of the COMACHI study.
In conclusion, the results from the COMACHI study suggest a similar efficacy and safety profile for pertuzumab plus trastuzumab and docetaxel in Japanese patients compared with patients in the overall population of the CLEOPATRA study. These results provide further evidence to support pertuzumab plus trastuzumab and docetaxel combination therapy as the standard of care for first-line treatment of Japanese patients with inoperable or recurrent HER2-positive breast cancer.
Acknowledgements
We would like to thank all the patients, investigators, clinicians, and research staff who participated in this trial. This work was supported by Chugai Pharmaceutical Co., Ltd. Support for third-party writing assistance for this manuscript, furnished by Katie Wilson, PhD, and Stephen Salem, BSc, of Health Interactions, was provided by Chugai Pharmaceutical Co., Ltd.
Compliance with ethical standards
Conflict of interest
All authors received support for third-party writing assistance for this manuscript, furnished by Katie Wilson, PhD, and Stephen Salem, BSc, both of Health Interactions. Masato Takahashi has received honoraria from AstraZeneca, Taiho, Chugai, Novartis, Pfizer, Kyowa Kirin, Eli Lilly, Daiichi Sankyo, Eisai, Allergan, Fujiyakuhin, and Nihon Medi Physics, a manuscript fee from Asahi Shimbun, grant support from Taiho, Chugai, Fujifilm Toyama Chemical, Eisai, Daiichi Sankyo, and Kyowa Kirin. Shoichiro Ohtani has received honoraria from AstraZeneca, Chugai, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo. Shigenori Nagai has received honoraria from Novartis, Pfizer, Eli Lilly, Eisai, Taiho Oncology, Nippon Kayaku, and Chugai. Seiki Takashima, Miki Yamaguchi, and Michiko Tsuneizumi have received research funding from Chugai for this study. Tomofumi Osako has received research funding from Chugai, Nippon Kayaku, and Eli Lilly, and honoraria from Chugai, Eli Lilly, and Pfizer. Yoshifumi Komoike has received honoraria from AstraZeneca, Chugai, Pfizer, Novartis, and Eli Lilly, and grant support from Daiichi Sankyo, Taiho, MSD, and Chugai. Yoshinori Ito has received grant support from Covance Japan, IQVIA Services Japan, MSD, AstraZeneca, A2 Healthcare, Novartis, Parexel, Kyowa Kirin, Chugai, Eli Lilly, Eisai, EPS, Daiichi Sankyo, and Taiho. Masahiko Ikeda has received honoraria from Chugai, Pfizer, Kyowa Kirin, Eisai, Novartis, Daiichi Sankyo, Asahi Kasei, Ono, Mundi, Taiho, Bayer, and Nippon Kayaku, and has received grant support from Hisamitsu and a consulting fee from Chugai, belongs to Japanese Breast Cancer Society as a member of Practice Guidelines Committee, and Chairman of Epidemiology and Prevention Subcommittee in Practice Guidelines Committee, Setouchi Breast Project as a director, and Chairman of Clinical Trials Committee. Kazushige Ishida had received honoraria from Chugai, Nippon Kayaku, Eisai, and Pfizer. Takahiro Nakayama has received honoraria from Chugai, Novartis, AstraZeneca, Eli Lilly, Taiho Oncology, Takeda, and Pfizer. Tsutomu Takashima has received honoraria from Chugai, Eisai, Taiho Oncology, Novartis, Pfizer, Eli Lilly, and Daiichi Sankyo. Takashi Asakawa, Sho Matsumoto, and Daisuke Shimizu are employees of and hold stocks in Chugai. Norikazu Masuda has received honoraria (e.g., lecture fees) from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, and Takeda, and has received research funding from Chugai, AstraZeneca, Kyowa Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Gynäkologie erhalten Sie Zugang zu CME-Fortbildungen der beiden Fachgebiete, den Premium-Inhalten der Fachzeitschriften, inklusive einer gedruckten gynäkologischen oder urologischen Zeitschrift Ihrer Wahl.
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
